Author

Nadine Clemo

ORCID: 0009-0001-7248-0088

Observed ORCID: 0009-0001-7248-0088

OpenAlex ID: A5109731175

First results from the Phase 1 study of APL-4098, an oral potent GCN2 inhibitor for the treatment of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) and Myelodysplastic Syndromes (MDS)/AML

2025 · Shaun Fleming, Shuhying Tan, et al. · Blood · 3

A Novel Potent and Selective GCN2 Inhibitor, APL-4098, Has Antileukemic Activity through Dysregulation of Mitochondrial Function

2026 · Mónica Román-Trufero, Gavin Whitlock, et al. · Clinical Cancer Research · 2

Efficacy of GCN2 inhibition by a novel small molecule AP030 in acute leukemia.

2024 · Nadine Clemo, Monica Roman-Trufero, et al. · Journal of Clinical Oncology · 2

Abstract 618: Preclinical assessment of APL-030, a selective and orally bioavailable inhibitor of the integrated stress response regulator GCN2 with activity against acute myeloid leukemia

2024 · Monica Roman-Trufero, Gavin Whitlock, et al. · Cancer Research · 2

Nonclinical evaluation of APL-4098, a novel GCN2 kinase inhibitor, reveals potent anti-leukemic effects through mitochondrial stress induction and synergy with venetoclax, targeting AML blasts and LSCs

2025 · Monica Roman-Trufero, Kevin Blighe, et al. · Blood · 1

Discovery of a Protein Kinase R-like Endoplasmic Reticulum Kinase (PERK) Inhibitor Suitable for Clinical Progression

2026 · Paul A. Glossop, Samuel Brookes, et al. · Journal of Medicinal Chemistry

OC 76.2 A novel monoclonal antibody directed against the C-domains of Von Willebrand Factor inhibits function in a shear-dependent manner and reverses the thrombotic phenotype in TTP

2026 · Michael Appiah, Golzar Mobayen, et al. · Research and Practice in Thrombosis and Haemostasis

Supplementary Data2 from A Novel Potent and Selective GCN2 Inhibitor, APL-4098, Has Antileukemic Activity through Dysregulation of Mitochondrial Function

2026 · Mónica Román-Trufero, Gavin Whitlock, et al.

Supplementary Data1 from A Novel Potent and Selective GCN2 Inhibitor, APL-4098, Has Antileukemic Activity through Dysregulation of Mitochondrial Function

2026 · Mónica Román-Trufero, Gavin Whitlock, et al.

Data from A Novel Potent and Selective GCN2 Inhibitor, APL-4098, Has Antileukemic Activity through Dysregulation of Mitochondrial Function

2026 · Mónica Román-Trufero, Gavin Whitlock, et al.

Abstract 1726: Preclinical development of APL-045: A selective PERK inhibitor targeting ER stress pathways in cancer

2025 · Krishna Kolluri, Clara Stead, et al. · Cancer Research

Works count: 11

Citation count: 10

H-index: 2

I10-index: